Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Merck & Co., Inc.MRK · Entity 2807 | EVP, Specialty, Pharma, & ID | May 05, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Merck & Co., Inc.
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2029-05-05 | Direct | 10,605 |
Reported balance
After 2026-05-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-05 · Grant · Acquired 10,605 · Balance 10,605 F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2029-05-05 | Direct | 35,351 |
Reported balance
After 2026-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-05 · Grant · Acquired 35,351 · Balance 35,351 F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $113.15 · Expires 2036-05-04 | Direct | 31,044 |
Reported balance
After 2026-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-05 · Grant · Acquired 31,044 · Balance 31,044 F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock.
F2: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
F3: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2026 Filed May 7, 2026 15:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantStock Option (Right to Buy) · Derivative | 31,044 | $0.00 Strike: $113.15 | $0.00 |
DisclosureSEC source: 0000310158-26-000125 · form4.xml · derivative · entry 3 Foard Brian · CIK 0002119564 · EVP, Specialty, Pharma, & ID 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,044 Underlying: Common Stock · 31,044 shares Expires 2036-05-04 F3 · derivative.exercise_date: The option vests and becomes exercisable in equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| May 05, 2026 Filed May 7, 2026 15:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 35,351 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000125 · form4.xml · derivative · entry 2 Foard Brian · CIK 0002119564 · EVP, Specialty, Pharma, & ID 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,351 Underlying: Common Stock · 35,351 shares Expires 2029-05-05 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
| May 05, 2026 Filed May 7, 2026 15:48 UTC | Merck & Co., Inc. MRK · Entity 2807 | GrantRestricted Stock Unit · Derivative | 10,605 | $0.00 | $0.00 |
DisclosureSEC source: 0000310158-26-000125 · form4.xml · derivative · entry 1 Foard Brian · CIK 0002119564 · EVP, Specialty, Pharma, & ID 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,605 Underlying: Common Stock · 10,605 shares Expires 2029-05-05 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Merck & Co., Inc. common stock. F2 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Merck & Co., Inc. common stock in three equal installments on 5/5/2027, 5/5/2028, and, 5/5/2029. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.